Alecardio

Effect Of Aleglitazar On Cardiovascular Outcomes After Acute Coronary Syndrome With Type 2 Diabetes Mellitus.

  • Alecardio was a Phase III, multi-center, randomized double blind, placebo-controlled trial
  • Conducted in 720 hospitals in 26 countries throughout North America, Latin America, Europe and Asia-Pacific regions
  • The enrollment of 7,226 patients hospitalized for ACS (myocardial infarction or unstable angina) with type 2 diabetes occurred between February 2010 and May 2012
  • Treatment was planned to continue until patients were followed-up for at least 2.5 years and 950 primary end point events were positively adjudicated

Study Metrics

Sites Initiated

32

Sites Randomized

25

Patients Screened

175

Patients Randomized

154